Daraxonrasib shrank tumors in over 30% of patients with previously treated RAS-mutant non-small cell lung cancer.
- In the news
Lung Cancer Treatments and Mutations
Moving in Cancer Cell, Cancer Discovery and New England Journal of Medicine.
- Moved, week to 22 Oct 2026
- 3
- Papers in 60 days
- 21
Add Lung Cancer Treatments and Mutations as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest
Rebuilt
Moved this week
Firmonertinib shows promising systemic and intracranial efficacy in preclinical models of PACC-mutant NSCLC, supporting its further clinical development.
Selpercatinib significantly improves 2-year event-free survival in early-stage RET fusion-positive NSCLC, reaching 92% in stage II/IIIA patients compared to 61% with placebo.
- 14 cites
Latest in Lung Cancer Treatments and Mutations
Newest first · last 60 days
TRI-611 is the first clinical-stage molecular glue degrader targeting ALK fusion proteins, achieving tumor regression in ALK-positive NSCLC models.
A 7-gene M2 macrophage-associated signature predicts osimertinib resistance in lung adenocarcinoma, with RRBP1 showing the strongest link to survival.
- Open access
Mitochondrial dysfunction and genetic-epigenetic cascades drive drug-tolerant states across lung cancer subtypes.
- Open access
Population data reveal the historical origin of a rare genetic variant linked to increased lung cancer risk.
Germline EGFR T790M mutation significantly increases lung cancer risk, especially in never-smokers, surpassing the risk from smoking in over 3.3 million individuals.
A rare inherited EGFR mutation has persisted in Southern Appalachia since the 1700s, now affecting populations and increasing lung cancer risk.
Small cell lung cancer exhibits a high 80% rate of brain metastases driven by neurotropic mechanisms and resistance to current therapies.
Virtual tumor models accurately predict personalized therapeutic combinations for NSCLC, identifying 53BP1 as a promising target and stratifying patients for radiotherapy.
Detection of molecular residual disease via circulating tumor DNA identifies high recurrence risk in resectable solid tumor patients, enabling more efficient clinical trials.
Tambotatug pelitecan significantly improves survival and response rates in relapsed small-cell lung cancer compared to topotecan, with fewer severe adverse events.
Six proteomic aging clocks consistently predicted lower biological age in a 12-week clinical trial of rentosertib for idiopathic pulmonary fibrosis.
- Open access
Heterogeneous resistance mechanisms, including EGFR mutations, bypass signaling, and transformation, emerge in EGFR T790M-positive lung adenocarcinoma after 14.2 months of osimertinib treatment.
- Open access
Small-molecule inhibitors targeting RAS/RAF disrupt allosteric RAF conformation, effectively treating diverse RAS-driven cancers with a broad-spectrum approach.
- Open access
Add Lung Cancer Treatments and Mutations as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6244
- medRxiv1789
- PNAS447
- Sci Adv354
- JAMA268
- Environ Res246
- BMJ196
- Nat Commun173
- Environ Pollution167
- Nature151
- Applied & Environ Microbio145
- Science141
- Lancet128
- Cell Rep127
- NEJM119
- Plant Cell Environ118
- J Exp Bot107
- mBio107
Topics moving, week to 22 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Cancer Immunotherapy and Biomarkers5
- Gut microbiota and health5
- Cancer Genomics and Diagnostics4
- Bacteriophages and microbial interactions4
- CAR-T cell therapy research3
- Lung Cancer Treatments and Mutations3
- Liver Disease Diagnosis and Treatment3
- Dementia and Cognitive Impairment Research3